Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.7 Million SEK | -96.6% |
| 2022 | 79.4 Million SEK | 11.67% |
| 2021 | 71.1 Million SEK | 12.32% |
| 2020 | 63.3 Million SEK | -8.53% |
| 2019 | 69.2 Million SEK | 18.9% |
| 2018 | 58.2 Million SEK | -8.55% |
| 2017 | 63.64 Million SEK | -0.74% |
| 2016 | 64.11 Million SEK | 42.4% |
| 2015 | 45.02 Million SEK | 34.67% |
| 2014 | 33.43 Million SEK | 43.39% |
| 2013 | 23.31 Million SEK | 43.03% |
| 2012 | 16.3 Million SEK | 227.25% |
| 2011 | 4.98 Million SEK | 79.31% |
| 2010 | 2.77 Million SEK | 413.97% |
| 2009 | 540.52 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 24.2 Million SEK | 10.0% |
| 2024 Q3 | 18.5 Million SEK | -23.55% |
| 2024 Q1 | 22 Million SEK | -10.57% |
| 2023 Q3 | 21.3 Million SEK | -27.05% |
| 2023 FY | 2.7 Million SEK | -96.6% |
| 2023 Q2 | 29.2 Million SEK | 23.21% |
| 2023 Q4 | 24.6 Million SEK | 15.49% |
| 2023 Q1 | 23.7 Million SEK | -2.47% |
| 2022 Q2 | 19.5 Million SEK | 21.12% |
| 2022 FY | 79.4 Million SEK | 11.67% |
| 2022 Q1 | 16.1 Million SEK | -18.27% |
| 2022 Q4 | 24.3 Million SEK | 35.0% |
| 2022 Q3 | 18 Million SEK | -7.69% |
| 2021 Q3 | 16.2 Million SEK | -10.5% |
| 2021 FY | 71.1 Million SEK | 12.32% |
| 2021 Q2 | 18.1 Million SEK | 5.85% |
| 2021 Q4 | 19.7 Million SEK | 21.6% |
| 2021 Q1 | 17.1 Million SEK | 6.21% |
| 2020 FY | 63.3 Million SEK | -8.53% |
| 2020 Q3 | 15.4 Million SEK | 10.0% |
| 2020 Q4 | 16.1 Million SEK | 4.55% |
| 2020 Q2 | 14 Million SEK | -21.35% |
| 2020 Q1 | 17.8 Million SEK | -4.81% |
| 2019 FY | 69.2 Million SEK | 18.9% |
| 2019 Q1 | 14.3 Million SEK | -6.54% |
| 2019 Q2 | 18.5 Million SEK | 29.37% |
| 2019 Q3 | 17.8 Million SEK | -3.78% |
| 2019 Q4 | 18.7 Million SEK | 5.06% |
| 2018 Q4 | 15.3 Million SEK | 19.53% |
| 2018 FY | 58.2 Million SEK | -8.55% |
| 2018 Q2 | 16.2 Million SEK | 9.46% |
| 2018 Q3 | 12.8 Million SEK | -20.99% |
| 2018 Q1 | 14.8 Million SEK | -10.14% |
| 2017 Q3 | 14.04 Million SEK | 3.16% |
| 2017 Q2 | 13.61 Million SEK | -30.17% |
| 2017 Q4 | 16.47 Million SEK | 17.23% |
| 2017 Q1 | 19.5 Million SEK | 1.09% |
| 2017 FY | 63.64 Million SEK | -0.74% |
| 2016 Q4 | 19.29 Million SEK | 22.56% |
| 2016 Q3 | 15.74 Million SEK | -7.14% |
| 2016 Q1 | 12.12 Million SEK | -16.64% |
| 2016 Q2 | 16.95 Million SEK | 39.79% |
| 2016 FY | 64.11 Million SEK | 42.4% |
| 2015 Q3 | 11.05 Million SEK | -5.05% |
| 2015 Q1 | 7.77 Million SEK | -4.69% |
| 2015 Q4 | 14.54 Million SEK | 31.56% |
| 2015 FY | 45.02 Million SEK | 34.67% |
| 2015 Q2 | 11.64 Million SEK | 49.9% |
| 2014 Q3 | 7.49 Million SEK | -20.39% |
| 2014 FY | 33.43 Million SEK | 43.39% |
| 2014 Q2 | 9.41 Million SEK | 12.51% |
| 2014 Q1 | 8.36 Million SEK | 31.93% |
| 2014 Q4 | 8.15 Million SEK | 8.75% |
| 2013 Q1 | 5.38 Million SEK | -10.33% |
| 2013 Q2 | 6.64 Million SEK | 23.6% |
| 2013 FY | 23.31 Million SEK | 43.03% |
| 2013 Q4 | 6.34 Million SEK | 28.31% |
| 2013 Q3 | 4.94 Million SEK | -25.65% |
| 2012 Q1 | 3.7 Million SEK | 84.59% |
| 2012 Q2 | 3.41 Million SEK | -7.78% |
| 2012 Q3 | 3.18 Million SEK | -6.56% |
| 2012 Q4 | 6 Million SEK | 88.16% |
| 2012 FY | 16.3 Million SEK | 227.25% |
| 2011 Q4 | 2 Million SEK | 62.07% |
| 2011 FY | 4.98 Million SEK | 79.31% |
| 2011 Q2 | 2.09 Million SEK | 192.69% |
| 2011 Q1 | 714.88 Thousand SEK | -13.0% |
| 2011 Q3 | 1.23 Million SEK | -40.88% |
| 2010 FY | 2.77 Million SEK | 413.97% |
| 2010 Q2 | 1.01 Million SEK | 131.04% |
| 2010 Q4 | 821.69 Thousand SEK | -16.48% |
| 2010 Q1 | 439.98 Thousand SEK | 0.0% |
| 2010 Q3 | 983.88 Thousand SEK | -3.21% |
| 2009 FY | 540.52 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 96.741% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.559% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.559% |
| Arcoma AB | 53.25 Million SEK | 94.93% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | 45.663% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.905% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 98.717% |
| CellaVision AB (publ) | 295.99 Million SEK | 99.088% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 96.083% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -106.235% |
| C-Rad AB (publ) | 3.8 Million SEK | 28.947% |
| Duearity AB (publ) | 21.58 Million SEK | 87.491% |
| Dignitana AB (publ) | 74.73 Million SEK | 96.387% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.975% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | 85.188% |
| Iconovo AB (publ) | 63.35 Million SEK | 95.738% |
| Integrum AB (publ) | 90.57 Million SEK | 97.019% |
| Luxbright AB (publ) | 23.09 Million SEK | 88.307% |
| Mentice AB (publ) | 237.06 Million SEK | 98.861% |
| OssDsign AB (publ) | 175.6 Million SEK | 98.462% |
| Paxman AB (publ) | 133.8 Million SEK | 97.982% |
| Promimic AB (publ) | 48.55 Million SEK | 94.439% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 98.337% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 96.142% |
| ScandiDos AB (publ) | 61.03 Million SEK | 95.577% |
| Sectra AB (publ) | 39.06 Million SEK | 93.088% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 98.453% |
| Senzime AB (publ) | 141.51 Million SEK | 98.092% |
| SpectraCure AB (publ) | 12.12 Million SEK | 77.737% |
| Stille AB | 87.21 Million SEK | 96.904% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.951% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 99.388% |